Search
forLearn
5 / 801 resultslearn Peach Kernel
learn beeswax
learn peach leaf
learn Apricot
Research
5 / 1000+ results
research Phrynoderma and acquired acrodermatitis enteropathica in breastfeeding women after bariatric surgery
Women who had bariatric surgery risk nutritional deficiencies causing skin issues during pregnancy and breastfeeding.
research Skin Signs of Zinc Deficiency in Children: A clinical study in Jordan.
Zinc deficiency in children can cause skin issues and is often overlooked.
research Acquired Zinc Deficiency Dermatosis in Man
Zinc supplements can resolve skin issues caused by zinc deficiency.
research ACUTE ZINC DEPLETION SYNDROME DURING PARENTERAL HYPERALIMENTATION
A patient with zinc depletion improved after zinc supplementation during parenteral nutrition.
research Alopezien – Diagnostisches und therapeutisches Management
Early diagnosis and personalized treatment are crucial for managing different types of alopecia effectively.
Community Join
5 / 1000+ resultscommunity Track hairline of Pelage executives
Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.
community Quote from Pelage (PP-405) Spokesperson...
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
community Does anyone know any hair serum with copper peptides in it?
community The use of peptides to enhance hair growth from wounding
community Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.